USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: AGILE SCIENCES, INC.
Address: 1791 Varsity Dr.
RALEIGH, NC
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: (919) 457-3308

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,924,302.00 6
SBIR Phase II $1,030,274.00 1
STTR Phase I $1,178,162.00 4

Award List:

STTR Phase I: Increasing the Efficiency of Membrane Filtration for Drinking Water Purification through the Incorporation of Novel Anti-Biofilm Small Molecules

Award Year / Program / Phase: 2009 / STTR / Phase I
Agency: NSF
Research Institution: North Carolina State University
Principal Investigator: Stephen McCall, DPhil
Award Amount: $149,999.00
RI Contact: John Chaffee
Abstract:
This award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5). This Small Business Technology Transfer Phase I Project tests the feasibility of applying Agile Sciences' technology to decreasing or eliminating biofouling on filtration membranes used for drinking… More

Targeting Oral Biofilms with 2-Aminoimidazole/Triazole Conjugates

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Eva Garland
Award Amount: $251,837.00
Abstract:
DESCRIPTION (provided by applicant): Dental caries, or tooth decay, affects hundreds of millions of people each year, and is second only to the common cold in its prevalence world-wide. New therapeutics to aid in the prevention of dental caries would repr esent a significant advancement in oral… More

Prevention of Bacterial Biofilms on CSF Shunts through the Incorporation of Novel

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen R. Brand
Award Amount: $570,115.00
Abstract:
DESCRIPTION (provided by applicant): This NIH SBIR project assesses the feasibility of applying a discovery made by the cofounders of Agile Sciences, Inc. to developing a more effective therapeutic strategy toward preventing bacterial infections associated with CSF shunts. Bacterial infections… More

SBIR Phase I: Preventing Biofilms on Indwelling Medical Devices with Novel Anti-Biofilm Small Molecules

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: NSF
Principal Investigator: Stephen R. Brand
Award Amount: $150,000.00
Abstract:
This Small Business Innovation Research (SBIR) Phase I project describes a new approach for reducing infections associated with indwelling medical devices. Bacteria on medical devices are particularly challenging to treat because they form a protective matrix called a biofilm on the surface of the… More

Development of Small Molecules to Combat Bacterial Biofilms

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Sam Reyes – 919-457-3308
Award Amount: $545,129.00
Abstract:
DESCRIPTION (provided by applicant): Bacterial infections are responsible for an estimated 100,000 deaths in the United States each year, and despite the dire unmet medical need, few new treatment options are being developed. One of the most significant hurdles in effectively treating bacterial… More

Development of Novel Anti-Biofilm Compounds for Treating Chronic Wounds

Award Year / Program / Phase: 2011 / STTR / Phase I
Agency: HHS
Research Institution: MONTANA STATE UNIVERSITY
Principal Investigator: Laura M. Guogas – 919-457-3308
Award Amount: $300,000.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Chronic wounds that fail to respond to traditional therapeutic interventions afflict millions of people each year, and direct costs associated with treating these wounds are estimated at 5 to 10 billion annually. Eradication of pathogenic… More

Anti-biofilm agents for treating pulmonary infection in Cystic Fibrosis patients

Award Year / Program / Phase: 2011 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF NORTH CAROLINA
Principal Investigator: Laura M. Guogas – 919-457-3308
Award Amount: $428,163.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Cystic fibrosis (CF) is the most common life shortening inherited disorder amongst Caucasians, and Pseudomonas aeruginosa pulmonary infections are the leading cause of mortality in CF patients. Treatment of patients infected with P. aeruginosa is complicated by… More

Targeting Oral Biofilms with 2-Aminoimidazole/Triazole Conjugates

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Angela M. Pollard – 919-457-3308
Award Amount: $1,030,274.00
Abstract:
DESCRIPTION (provided by applicant): Dental caries is one of the most prevalent diseases in the U.S. with 85% of adults and the majority of children having been treated for at least one incidence. While this disease impacts all individuals, it is especially an issue for those of low economic status… More

SBIR Phase I: Enhancing the Bactericidal Activity of Copper: An Economically Viable Solution for Lowering Copper Usage Rates in Agriculture

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: NSF
Principal Investigator: Samuel O. Reyes
Award Amount: $150,000.00
Abstract:
This Small Business Innovation Research Phase I project describes a cost-effective method for reducing the quantities of copper used for agricultural crop protection. Currently, millions of pounds of copper are being sprayed onto plants each year. This copper is released into the environment,… More

Small Molecules to Enhance Bacterial Susceptibility to Antiseptics

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Angela M. Pollard – 919-457-3308
Award Amount: $257,221.00
Abstract:
DESCRIPTION (provided by applicant): One-third of costs associated with hospital acquired infections (HAIs) are attributed to surgical site infections (SSIs), and SSIs result in a two-fold increase in patient mortality rates. SSIs are most often caused byflora from the patients skin that enter the… More

Evaluation of a new class of molecules for treating MRSA infective endocarditis

Award Year / Program / Phase: 2013 / STTR / Phase I
Agency: HHS
Research Institution: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE/UCLA
Principal Investigator: Angela M. Pollard – 919-457-3308
Award Amount: $300,000.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Patients with infective endocarditis (IE) have a poor prognosis with one third of the patients succumbing to the infection within the first year. Treatments for endocarditis involve antibiotic therapy and/or surgery that cost upwards of 100,000 per patient;… More